Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity
Retinopathy of prematurity (ROP) is a neovascular retinal disease that has usually been treated by peripheral argon laser coagulation. Retinal laser coagulation has disadvantages and adverse effects such as the need for general anesthesia, scarring of the peripheral retina and choroid, and...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article (Journal) Editorial |
| Language: | English |
| Published: |
2012
|
| In: |
Archives of ophthalmology
Year: 2012, Volume: 130, Issue: 6, Pages: 800-801 |
| ISSN: | 1538-3601 |
| DOI: | 10.1001/archophthalmol.2012.1 |
| Online Access: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1001/archophthalmol.2012.1 Verlag, kostenfrei, Volltext: https://jamanetwork.com/journals/jamaophthalmology/fullarticle/1182272 
|
| Author Notes: | Bjoern C. Harder, MD, Stefan von Baltz, MD, Frank C. Schlichtenbrede, MFD, Jost B. Jonas, MD |
| Summary: | Retinopathy of prematurity (ROP) is a neovascular retinal disease that has usually been treated by peripheral argon laser coagulation. Retinal laser coagulation has disadvantages and adverse effects such as the need for general anesthesia, scarring of the peripheral retina and choroid, and... |
|---|---|
| Item Description: | Gesehen am 07.08.2018 |
| Physical Description: | Online Resource |
| ISSN: | 1538-3601 |
| DOI: | 10.1001/archophthalmol.2012.1 |